Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 March 2017
PRAC concludes a safety referral and starts one; decides to hold first public hearing
At its March meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) concluded a safety review and started a new one for which there will be a public hearing. The PRAC also started the review of docetaxel-containing medicines in the context of a safety signal and discussed three ongoing referrals.
PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations
The PRAC has recommended the suspension of the marketing authorisations for four linear gadolinium contrast agents because of evidence that small amounts of the gadolinium they contain are deposited in the brain. Evidence has not shown signs of harm.
The agents concerned are intravenous injections of gadobenic acid, gadodiamide, gadopentetic acid and gadoversetamide, which are given to patients to enhance images from magnetic resonance imaging (MRI) body scans.
Although no symptoms or diseases linked to gadolinium in the brain have been reported, the PRAC took a precautionary approach, noting that data on the long-term effects in the brain are limited.
More information is available below.
New review of valproate use in pregnancy and women of childbearing age
The PRAC has started a new review of the use of valproate-containing medicines in the treatment of women and girls who are pregnant or of childbearing age. These medicines are approved nationally in the European Union (EU) to treat epilepsy, bipolar disorder and in some countries, migraine.
In a previous review in 2014, the European Medicines Agency (EMA) agreed on measures to strengthen warnings and restrictions on valproate use in women and girls, due to the risk of malformations and developmental problems in babies who are exposed to valproate in the womb.
Concerns have since been raised about how effective these measures are. Therefore, the French medicines regulator, ANSM, asked EMA to review the measures and consider whether further EU-wide action should be recommended to minimise the risks in women who are pregnant or of childbearing age.
First public hearing to be organised on valproate
The PRAC has decided to organise a public hearing as part of the review of valproate to listen directly to the experience of EU citizens with these medicines, so this can be taken into account in the Committee’s recommendation.
The PRAC is expected to set a date for its first public hearing at its meeting in June, when it has conducted a first round of evaluation of the available scientific evidence. The hearing will be announced prominently on the Agency’s website together with a list of specific questions on which information from the public is sought and information on the date, time, location and how to register.
This is the first time the PRAC will hold a public hearing during a safety review of a medicine. It follows the adoption of rules of procedure on the organisation and conduct of public hearings and a simulation training in 2016. Public hearings will give EU citizens a voice in the evaluation of the safety of medicines and empower them to express their views on issues related to the safety of certain medicines and the management of risks.
More about the safety review of valproate is available below.
PRAC investigates cancer medicine docetaxel
The PRAC is investigating the cancer medicine docetaxel following cases of neutropenic enterocolitis in patients in France. Most of the patients were being treated for operable breast cancer.
A preliminary assessment by the PRAC indicates that the frequency of this known side effect has not increased in the last two years. A thorough evaluation of available data is being carried out and final conclusions will be published once the review has been completed.
More information is available below.
|Agenda - PRAC draft agenda of meeting 6-9 March 2017|
Start of referrals
|Valproate and related substances|
Recommendation by PRAC
|Gadolinium-containing contrast agents|
Safety signal evaluation
|Ongoing signal evaluation|
|Article-31 referral: Paracetamol-modified release||Under evaluation||PRAC adopted a list of outstanding issues|
|Article-31 referral: Medicinal products containing lactose of bovine origin for IV/IM use in acute allergic reactions||Under evaluation||PRAC adopted a list of outstanding issues|
|Article-31 referral: Factor VIII||Under evaluation||PRAC adopted a list of outstanding issues|
|Article-31 referral: Retinoid-containing medicinal products||Under evaluation||On 3 March 2017, as part of this review, EMA organised a meeting with patients’ organisations and healthcare professionals who work in the area of psoriasis, acne and women’s health. The participants expressed their views as regards a PRAC list of questions on how to improve awareness, understanding and compliance with retinoids’ pregnancy prevention programme. The outcome of the meeting will be reported back to the PRAC in May 2017 to feed into the review and contribute to the PRAC recommendation later in 2017.|
|Article-31 referral: Systemic and inhaled quinolone and fluoroquinolone antibiotics||Under evaluation||PRAC continued its assessment|
How useful is this page?
Average rating:Based on 10 ratings
Add your rating:
- See all ratings
3 ratings0 ratings1 ratings2 ratings4 ratings
- PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations (10/03/2017)
- Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 March 2017
- PRAC: Agendas, minutes and highlights
- Pharmacovigilance Risk Assessment Committee (PRAC)
- Acronyms and abbreviations used in PRAC minutes (2014-07-22)